Experimental cell therapy targets dangerous virus in vulnerable transplant patients
NCT ID NCT02982902
Summary
This early-stage study is testing whether specially selected immune cells from a donor can safely treat cytomegalovirus (CMV) infections in people who have received a stem cell transplant. The trial is for patients whose CMV infection isn't improving with standard antiviral medications. Researchers will collect T-cells from a donor, select those that target CMV, and infuse them into the patient to help their immune system fight the virus.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
RECRUITINGCleveland, Ohio, 44106-5065, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.